GlassScriptPhysician profile
William V Bingham
NPI 1275613408
$10,930.96
in general payments reported to CMS, 2019-2025
34 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $414 · 2021: $1,305 · 2022: $2,951 · 2023: $1,762 · 2024: $2,191 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,794 · Travel and Lodging: $738 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,793.81 |
| Travel and Lodging | $737.69 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $3,186.14 | 2022-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $1,351.04 | 2019-2025 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $922.91 | 2019-2025 | Erleada, Akeega, Balversa |
| Pfizer INC. | $612.92 | 2019-2025 | |
| Medtronic, INC. | $530.61 | 2021-2025 | Interstim, Altaviva |
| Sumitomo Pharma America, INC. | $451.31 | 2023-2025 | Gemtesa |
| Axonics, INC. | $423.39 | 2020-2024 | Axonics, Bulkamid |
| Endo Pharmaceuticals INC. | $419.03 | 2021-2023 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $388.46 | 2021-2025 | Prolaris |
| Boston Scientific Corporation | $376.46 | 2019-2025 | Ams 700, Axonics |
| Procept Biorobotics Corporation | $365.04 | 2023-2025 | Aquabeam Robotic System |
| Tolmar, INC. | $257.78 | 2023-2025 | Eligard, Jatenzo |
| Antares Pharma, INC. | $234.29 | 2019-2022 | |
| Endo USA, INC. | $203.93 | 2024-2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $193.30 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $156.81 | 2019-2025 | |
| Abbvie INC. | $151.86 | 2019-2024 | Lupron Depot |
| Comsort, INC | $100.00 | 2019 | |
| Urovant Sciences INC | $67.38 | 2021-2022 | |
| Photocure INC | $59.68 | 2024-2025 | Cysview |
| Bayer Healthcare Pharmaceuticals INC. | $55.60 | 2021 | |
| Smith+Nephew, INC. | $49.75 | 2023-2024 | Stravix Pl |
| Allergan, INC. | $49.34 | 2019-2021 | |
| Calyxo, INC. | $40.04 | 2025 | Cvac Aspiration System |
| Valencia Technologies Corporation | $39.78 | 2025 | Ecoin Device Kit |
| Medtronic USA, INC. | $35.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.81 | 2020 | |
| Neotract INC. | $33.36 | 2019 | |
| Sagent Pharmaceuticals | $31.86 | 2025 | Glydo |
| Abc Home Medical Supply, INC. | $26.23 | 2024 | |
| Convatec INC. | $24.11 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2025 | |
| Olympus America INC. | $20.41 | 2025 | Itind System |
| Clarus Therapeutics INC. | $17.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.